News & Media

 Keep up to date with all of our latest news.

News & Media Menu

At SparingVision, we are building a portfolio of synergistic cutting-edge #genomicmedicines for inherited #retinaldiseases (IRDs) spanning 3 core pillars. Watch below as our CSO Deniz Dalkara discusses our 1st pillar: mutation-agnostic gene therapies. #Ophthalmology #GeneTherapy

Watch the first in a new video series below as our CEO, @BoisselStephane, outlines our 3-pillar strategy within the #genomicmedicines space which encompasses: mutation-agnostic #genetherapy, #genomeediting & in vivo reprogramming. For more: #Ophthalmology